An Open-label, 3-Treatment, 3-Period, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Verinurad and Allopurinol When Administered Alone, and in Combination With Single Doses of Cyclosporine or Rifampicin
Latest Information Update: 29 Mar 2023
At a glance
- Drugs Allopurinol (Primary) ; Verinurad (Primary) ; Ciclosporin; Rifampicin
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 07 Dec 2020 Status changed from active, no longer recruiting to completed.
- 16 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2020 Planned number of patients changed from 48 to 14.